In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading
In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells. The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well. Continue reading
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas. Continue reading
In a recent Phase II clinical study, researchers report that mesenchymal stem cells were successful in relieving chronic lower back pain. The scientists injected MSCs directly into the degenerating vertebral disks of patients suffering from lower back pain, resulting in an overall reduction in the mean pain score, improved function for at least 12 months, and a reduced need for further surgical and non-surgical treatment interventions.
Of the 6 million Americans suffering from debilitating back pain today, 3.5 million are affected by degenerative invertebral disk disease. The results of this clinical trial show that, instead of addressing the symptoms, mesenchymal stem cells are able to treat the source of the pain for long lasting relief. According to lead researcher, Dr. Tory McJunkin, M.D, “This study shows we are progressing toward major advances in pain medicine,”
Mesenchymal stem cells have the unique capacity to regenerate a multitude of different types of tissues – such as neurons, insulin producing pancreatic beta cells, bone, cartilage, and cardiomyocites amongst them. This Phase II study is just one example of the utility of stem cells in successfully treating conditions previously thought to be untreatable or treatable only through invasive options. To learn how to bank your own valuable stem cells to insure access to emerging regenerative therapies, visit www.stemsave.com or call 877-783-6728 877-StemSave) today.
A medical team from the University of Calgary is now recruiting candidates to participate in the phase one clinical trial for a new stem cell therapy that aims to treat spinal cord injuries. The researchers plan to inject stem cells into the spinal cord two sites above and two sites below the point of injury to recreate lost or damaged tissue. Continue reading
Doctors from pain clinics across the country, such as the Arizona Pain Stem Cell Institute, are now offering stem cell therapies to patients suffering from plantar fasciitis. The new treatment involves injections of bone-derived stem cells to reduce inflammation and regenerate damaged tissue in the plantar fascia. Continue reading
Research teams from Cedars-Sinai Heart Institute and the Minneapolis Heart Institute with funding from CIRM [California Institute for Regenerative Medicine] are moving to Phase 2 Clinical Trials for a treatment that utilizes cardiac stem cells to repair severe heart damage. The treatment development was led by Eduardo Marbán, a director at the Cedars-Sinai Heart Institute and founder of Capricor. This groundbreaking treatment involves the injection of stem cells into the coronary artery, which then migrate to the heart and promote the regrowth of healthy heart muscle. Continue reading
Scientists from the Mediterranean Institute of Haematology have developed a treatment that utilizes stem cells from umbilical cord blood to cure children of a life-threatening blood disorder called Thalassemia Major. The procedure involves the transplantation of stem cells from cord blood into the Thalassemia patient. Recent applications [in India] of this breakthrough procedure have resulted in several children being cured of the disease. Continue reading
The Ninth Annual Stem Cell Summit will take place on February 18th in New York City. The summit will feature presentations from the stem cell industry’s premier researchers, executives, and investors to address recent advances and this year’s expectations of the Stem Cell / Regenerative Medical industry. Continue reading
Researchers at the Virginia Commonwealth University’s Masey Cancer Center have developed an innovative approach to the treatment of multiple myeloma. The Phase II Clinical trial involves a process to ‘mark’ cancerous cells and also boost the body’s immune system – by removing the patient’s stem cells, manipulating them in-vitro [outside the body] and then reintroducing the stem cells back into the patient – to destroy the cancerous cells. Researchers believe the reprogrammed stem cells will also prevent any future recurrence of multiple myeloma.